modelPeginterferonAlfa2a
Extends from Pharmacolibrary.Drugs.ATC.L.L03AB11.
Information
| name: | PeginterferonAlfa2a | |
| ATC code: | L03AB11 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 180 | mg |
| volume of distribution: | 8 | L |
| clearance: | 100 | ml/h |
| other parameters in model implementation | ||
Peginterferon alfa-2a is a pegylated form of interferon alfa-2a, an immunomodulatory drug used primarily in the treatment of chronic hepatitis B and C infections. By attaching polyethylene glycol (PEG) to interferon alfa-2a, the drug has an extended half-life, allowing for less frequent dosing. Peginterferon alfa-2a is approved and widely used for antiviral therapy, though its use has decreased with the advent of newer direct-acting antivirals for hepatitis C.
Pharmacokinetics
Pharmacokinetic parameters reported for adults with chronic hepatitis C, both male and female, under standard clinical dosing.
References
Jung, YS, et al., & Park, K (2018). Population PK-PD Model of Pegylated Interferon Alfa-2a in Healthy Korean Men. Journal of pharmaceutical sciences 107(12) 3171–3178. DOI:10.1016/j.xphs.2018.08.017 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30179597
Keating, GM, & Curran, MP (2003). Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 63(7) 701–730. DOI:10.2165/00003495-200363070-00008 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12656650
Howell, CD, et al., & Hoofnagle, JH (2008). Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 6(5) 575–583. DOI:10.1016/j.cgh.2008.02.035 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18407798
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)